نتائج البحث

Treatment Adherence and Health Status of Patients With COPD Under Treatment With Salmeterol/Fluticasone via the Elpenhaler® Device: The AHEAD Study.

• Authors : Exarchos KP; Respiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greece.; Hillas G

Subjects: Bronchodilator Agents*/Bronchodilator Agents*/Bronchodilator Agents*/administration & dosage ; Bronchodilator Agents*/Bronchodilator Agents*/Bronchodilator Agents*/therapeutic use ; Fluticasone-Salmeterol Drug Combination*/Fluticasone-Salmeterol Drug Combination*/Fluticasone-Salmeterol Drug Combination*/administration & dosage

• Source: The clinical respiratory journal [Clin Respir J] 2024 Jul; Vol. 18 (7), pp. e13803.Publisher: Blackwell Publishing Country of Publication: England NLM ID: 101315570 Publication Model: Print Cited Medium: Internet ISSN: 1752-699X

تفاصيل العنوان

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.

• Authors : Tashkin DP; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.; Ohar JA

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Asthma*/Asthma*/Asthma*/epidemiology ; Asthma*/Asthma*/Asthma*/physiopathology

• Source: Pulmonary medicine [Pulm Med] 2021 Mar 17; Vol. 2021, pp. 8881895. Date of Electronic Publication: 2021 Mar 17 (Print Publication: 2021).Publisher: Hindawi Pub. Corp Country of Publication: Egypt NLM ID: 101558762 Publication Model: eCollection Cited Medium: Internet ISSN:

تفاصيل العنوان

Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety.

• Authors : Suissa S; Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.

Subjects: Pneumonia*/Pneumonia*/Pneumonia*/epidemiology ; Pneumonia*/Pneumonia*/Pneumonia*/etiology ; Pulmonary Disease, Chronic Obstructive*

• Source: COPD [COPD] 2022; Vol. 19 (1), pp. 109-117.Publisher: Informa Healthcare Country of Publication: England NLM ID: 101211769 Publication Model: Print Cited Medium: Internet ISSN: 1541-2563

تفاصيل العنوان

Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging.

• Authors : Usmani O; Imperial College London and Royal Brompton Hospital, London, UK.; Li G

Subjects: Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/diagnostic imaging ; Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/drug therapy; Humans

• Source: Respiratory research [Respir Res] 2023 Sep 23; Vol. 24 (1), pp. 226. Date of Electronic Publication: 2023 Sep 23.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

• Source: Phase IV, 12-week, Single Arm, Open Label Study Evaluating the Safety and Efficacy of Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler in

تفاصيل العنوان

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination (RETRIEVE)

• Source: A Retrospective rEal-life daTa Study to Assess the Incidence of exaceRbations and Change in Lung functIon Forced Expiratory Volume (FEV1) in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts

تفاصيل العنوان

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).

• Authors : Skloot GS; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy. .; Chiesi USA, Inc., Cary, NC, USA. .

Subjects: Glycopyrrolate* ; Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/diagnostic imaging ; Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/Pulmonary Disease, Chronic Obstructive*/drug therapy

• Source: Respiratory research [Respir Res] 2023 Oct 06; Vol. 24 (1), pp. 244. Date of Electronic Publication: 2023 Oct 06.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease

• Source: A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease

تفاصيل العنوان

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

• Authors : Bjermer L; Department of Respiratory medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden.; van Boven JFM

Subjects: Models, Economic*; Cost-Benefit Analysis/Cost-Benefit Analysis/Cost-Benefit Analysis/*methods ; Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/Fluticasone-Salmeterol Drug Combination/*economics

• Source: Respiratory research [Respir Res] 2017 Dec 11; Vol. 18 (1), pp. 206. Date of Electronic Publication: 2017 Dec 11.Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

• Source: A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single

تفاصيل العنوان